التفاصيل البيبلوغرافية
| العنوان: |
Panobinostat and Multiple Myeloma in 2018. |
| المؤلفون: |
Yee, Andrew J., Raje, Noopur S. |
| المصدر: |
Oncologist; May2018, Vol. 23 Issue 5, p516-517, 2p |
| مصطلحات موضوعية: |
ENZYME inhibitors, MULTIPLE myeloma, DRUG approval |
| مستخلص: |
The article discusses the evolving strategy of using histone deacetylase (HDAC) inhibitors in multiple myeloma (MM). Panobinostat (LBH589) is an oral pan-HDAC inhibitor which is approved for treating relapsed MM and it is later re-evaluated as third-line therapy. Panobinostat has unique mechanism of action but has concerns such as diarrhea and cardiac events such as arrhythmias. |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder